Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy

Anand Srivastava, Beverley Adams-Huet, Gloria L Vega, Robert D Toto, Anand Srivastava, Beverley Adams-Huet, Gloria L Vega, Robert D Toto

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) can improve dyslipidemia in patients with diabetes and albuminuria. Whether combined ACEi+ARB or ACEi+mineralocorticoid receptor blockade improves dyslipidemia is not known. We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN). We measured lipid levels, very-low-density (V), intermediate-density (I), low-density (LDL), high-density (HDL) lipoprotein, LDL particle size with their respective cholesterol (C) and apolipoprotein B levels (ApoB), and urine albumin/creatinine ratio (UACR) at 12-week interval during a 48-week randomized, double-blind placebo-controlled trial in 81 patients with DN. Plasma lipids and lipoprotein C were analyzed enzymatically and Apo B was determined chemically. Data were analyzed by mixed model repeated measures. ΔUACR differed among treatment arms (placebo -24.6%, los -38.2%, spiro -51.6%, p=0.02). No correlation existed between ΔUACR and ΔTG or any of the lipid or lipoprotein measurements. Compared with placebo losartan, but not spironolactone, decreased TG (-20.9% vs +34.3%, p<0.01), V+I C(-18.8% vs +21.3%, p<0.01), and V+I-ApoB (-13.2% vs +21%, p<0.01). There were no significant changes in body weight, HbA1c or other lipoprotein variables. We conclude losartan improves dyslipidemia in patients with DN. We speculate the mechanism improved clearance of VLDL and remnant lipoproteins.

Trial registration number: NCT00381134; Results.

Keywords: Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Dyslipidemias; Proteinuria.

Copyright © 2016 American Federation for Medical Research.

Figures

Figure 1
Figure 1
(A) Per cent change of plasma triglycerides by treatment group triglyceride per cent change at week 48: +34.3% (placebo), 20.9% (losartan), −5.1% (spironolactone). (B). Absolute change in plasma triglyceride/HDL-cholesterol ratio by treatment group triglyceride/HDL per cent change at week 48: +2.9% (placebo), −1.4% (losartan), +0.8% (spironolactone). (C) Per cent change of very-low-density lipoprotein cholesterol (VLDL-C)+intermediate-density lipoprotein cholesterol (IDL)-C V+I-C by treatment group. Per cent change at week 48: +34.3% (placebo), −18.8% (losartan), −14.4% (spironolactone). (D) Per cent change of very-low-density lipoprotein ApoB (V-ApoB)+intermediate-density lipoprotein ApoB (I-ApoB) by treatment group. Per cent change at week 48: +21.0% (placebo), −13.2%, (losartan), −9.2% (spironolactone). The figures depict geometric mean (95% CI). p Values are from mixed-model repeated-measures analysis comparing treatment groups. Apo-B, apolipoprotein B.

References

    1. Adler S. Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int 2004;66:2095–106. 10.1111/j.1523-1755.2004.00988.x
    1. Adler AI, Stevens RJ, Manley SE, et al. . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32. 10.1046/j.1523-1755.2003.00712.x
    1. Keith DS, Nichols GA, Gullion CM, et al. . Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659–63. 10.1001/archinte.164.6.659
    1. Gaede P, Vedel P, Larsen N, et al. . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93. 10.1056/NEJMoa021778
    1. Ordonez JD, Hiatt RA, Killebrew EJ, et al. . The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638–42. 10.1038/ki.1993.292
    1. Vogt L, Laverman GD, Dullaart RP, et al. . Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction. Nephrol Dial Transplant 2004;19:5–8. 10.1093/ndt/gfg497
    1. Packard CJ, Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb 2004;11:6–14. 10.5551/jat.11.6
    1. Joven J, Villabona C, Vilella E, et al. . Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990;323:579–84. 10.1056/NEJM199008303230905
    1. Warwick GL, Caslake MJ, Boulton-Jones JM, et al. . Low-density lipoprotein metabolism in the nephrotic syndrome. Metab Clin Exp 1990;39:187–92. 10.1016/0026-0495(90)90074-M
    1. Muls E, Rosseneu M, Daneels R, et al. . Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 1985;54:225–37. 10.1016/0021-9150(85)90181-9
    1. Tseng CH. Differential dyslipidemia associated with albuminuria in type 2 diabetic patients in Taiwan. Clin Biochem 2009;42:1019–24. 10.1016/j.clinbiochem.2009.03.013
    1. de Sain-van der Velden MG, Kaysen GA, Barrett HA, et al. . Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998;53:994–1001. 10.1111/j.1523-1755.1998.00831.x
    1. Keane WF, Kasiske BL. Hyperlipidemia in the nephrotic syndrome. N Engl J Med 1990;9:603–4.
    1. Hadjadj S, Duly-Bouhanick B, Bekherraz A, et al. . Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004;30:43–51. 10.1016/S1262-3636(07)70088-5
    1. Cusick M, Chew EY, Hoogwerf B, et al. . Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 2004;66:1173–9. 10.1111/j.1523-1755.2004.00869.x
    1. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. . Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963–74.
    1. Keilani T, Schlueter WA, Levin ML, et al. . Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993;118:246–54. 10.7326/0003-4819-118-4-199302150-00002
    1. Wapstra FH, Van Goor H, Navis G, et al. . Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci 1996;90:393–401. 10.1042/cs0900393
    1. Ruggenenti P, Mise N, Pisoni R, et al. . Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003;107:586–92. 10.1161/01.CIR.0000047526.08376.80
    1. Mehdi UF, Adams-Huet B, Raskin P, et al. . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20:2641–50. 10.1681/ASN.2009070737
    1. Vega GL, Grundy SM. Quantitation of apolipoprotein B by chemical methods. Meth Enzymol 1996;263:63–82. 10.1016/S0076-6879(96)63005-5
    1. Vega GL, Cater NB, Hadizadeh DR III, et al. . Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther 2003;74:236–44. 10.1016/S0009-9236(03)00170-X
    1. Kyvelou SM, Vyssoulis GP, Karpanou EA, et al. . Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006;47:21–8.
    1. Lerch M, Teuscher AU, Beissner P, et al. . Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998;31:576–80. 10.1097/00005344-199804000-00016
    1. Derosa G, Ragonesi PD, Mugellini A, et al. . Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27:457–64. 10.1291/hypres.27.457
    1. Benson SC, Pershadsingh HA, Ho CI, et al. . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993–1002. 10.1161/01.HYP.0000123072.34629.57
    1. Keidar S, Kaplan M, Hoffman A, et al. . Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995;115:201–15. 10.1016/0021-9150(94)05514-J
    1. Sugimoto K, Kazdova L, Qi NR, et al. . Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens 2008;26:1209–15. 10.1097/HJH.0b013e3282f9b58a
    1. Fogari R, Maffioli P, Mugellini A, et al. . Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 2012;24:164–71. 10.1097/MEG.0b013e32834ba188
    1. Yusuf S, Teo KK, Pogue J, et al. . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–59. 10.1056/NEJMoa0801317
    1. Fried LF, Emanuele N, Zhang JH, et al. . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–903. 10.1056/NEJMoa1303154
    1. Bakris GL, Agarwal R, Chan JC, et al. . Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015;314:884–94. 10.1001/jama.2015.10081

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner